Auf dieser Seite
PTCT PTC Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Jul 30, 2026
$63,46
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$61,2352-Wochen-Tief
$90,8752-Wochen-Hoch
Marktkapitalisierung (MRQ)
$5.29B
P/E (TTM)
-117.5
EPS (TTM)
$-0.54
Umsatz (TTM)
$1.01B
Ihre Abzeichen
52W-Spanne
$61–$91
Analystenbewertung
BUY
Kursziel
$102
P/E
-117.5
ROE
20.6%
Nettogewinnmarge
-3.8%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
PTCT Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$63.46
Marktkapitalisierung (MRQ)
$5.29B
P/E (TTM)
-117.5
EPS (TTM)
$-0.54
Umsatz (TTM)
$1.01B
ROE (TTM)
20.6%
Verschuldungsgrad (MRQ)
-3.6
52W-Spanne
$61–$91
PTCT Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Über PTC Therapeutics, Inc. - Common Stock Unternehmensübersicht von Wikipedia
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.
Products
In 2017, PTC acquired Emflaza (deflazacort) from Marathon Pharmaceuticals. PTC also owns Translarna, (Ataluren) marketed for nonsense mutation Duchenne muscular dystrophy. Together, the two products generated revenues of 174 million dollars and 260 million dollars in 2017 and 2018 respectively.
PTC has the commercialization rights for WAYLIVRA (volanesorsen) in Latin America.
In 2018, PTC acquired Agilis Biotherapeutics and a gene therapy candidate, GT-AADC, with its compelling clinical data in treating aromatic L-amino acid decarboxylase (AADC) deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase (DDC) gene. As of 2024, the AAV based treatment for AADC deficiency has been approved by the FDA and commercialized in the United States as Kebilidi. It is the first FDA-approved gene therapy treatment for AADC deficiency. This same product was granted EMA approval for use in the European Union under the name Upstaza.
Pipeline
In 2020, PTC acquired Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth.
In 2020, PTC announced the FDA approval of Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older.
In 2024, Novartis has committed $1 billion upfront in a licensing deal with PTC Therapeutics for an experimental treatment for Huntington’s disease, with the potential for an additional $1.9 billion tied to achieving specific development, regulatory, and commercial milestones. PTC Therapeutics’ therapy, known as PTC518, is an oral medication designed to reduce the production of the mutant protein linked to the genetic mutation responsible for the disease. This mutant protein is believed to contribute to neuronal death, driving disease progression. In June, interim data from a Phase 2 trial indicated that PTC518 successfully lowered levels of the mutant protein in both blood and cerebrospinal fluid.
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
SektorHealthcare
BrancheBiotechnology
Mitarbeiter991
LandUS
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$1.73B2016-12-31 → 2025-12-31
EPS$7.782019-12-31 → 2025-12-31
Freier Cashflow$702M2016-12-31 → 2025-12-31
Nettogewinnmarge-3.8%2016-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | PTCT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | -117.55-Jahres-Durchschnitt ≈-2.7 | ≈-2.7 | · | · | |
| P/S (TTM) | 5.25-Jahres-Durchschnitt ≈3.8 | ≈3.8 | 55.0 | Unterbewertet | |
| K/B (MRQ) | -32.05-Jahres-Durchschnitt ≈481.5 | ≈481.5 | · | · | |
| EV / EBITDA (TTM) | 20.25-Jahres-Durchschnitt ≈-5.5 | ≈-5.5 | · | · | |
| Kurs / FCF (TTM) | -133.25-Jahres-Durchschnitt ≈-10.8 | ≈-10.8 | · | · | |
| Kurs / Cashflow (TTM) | -173.45-Jahres-Durchschnitt ≈-12.1 | ≈-12.1 | · | · | |
| EV / Umsatz (TTM) | 3.65-Jahres-Durchschnitt ≈3.0 | ≈3.0 | · | · | |
| EV / FCF (TTM) | -91.95-Jahres-Durchschnitt ≈-8.4 | ≈-8.4 | · | · | |
| Kurs / Materieller Buchwert (MRQ) | -9.3 | · | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | PTCT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Betriebsgewinnmarge (TTM) | 12.5%5-Jahres-Durchschnitt ≈-25.9% | ≈-25.9% | -24.1% | Spitzenklasse | |
| EBITDA-Marge (TTM) | 17.9%5-Jahres-Durchschnitt ≈-13.8% | ≈-13.8% | -24.1% | Spitzenklasse | |
| Vorgewinnmarge (TTM) | -6.6%5-Jahres-Durchschnitt ≈-43.8% | ≈-43.8% | -28.9% | Spitzenklasse | |
| Nettogewinnmarge (TTM) | -3.8%5-Jahres-Durchschnitt ≈-42.4% | ≈-42.4% | -38.1% | Spitzenklasse | |
| ROA (TTM) | -1.3%5-Jahres-Durchschnitt ≈-12.6% | ≈-12.6% | -27.7% | Spitzenklasse | |
| ROE (TTM) | 20.6%5-Jahres-Durchschnitt ≈-299.7% | ≈-299.7% | -40.8% | Schwach | |
| ROIC | 1044.7%5-Jahres-Durchschnitt ≈267.1% | ≈267.1% | -37.7% | Spitzenklasse |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | PTCT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital (MRQ) | -3.65-Jahres-Durchschnitt ≈74.5 | ≈74.5 | · | · | |
| Liquiditätsgrad (MRQ) | 3.45-Jahres-Durchschnitt ≈2.1 | ≈2.1 | 8.3 | Geringe Liquidität | |
| Quick Ratio (MRQ) | 3.25-Jahres-Durchschnitt ≈2.0 | ≈2.0 | 3.2 | Im Einklang | |
| Langfristige Schulden / Eigenkapital (MRQ) | -3.25-Jahres-Durchschnitt ≈65.1 | ≈65.1 | · | · |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | PTCT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 114.5%5-Jahres-Durchschnitt ≈41.2% | ≈41.2% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 35.3%5-Jahres-Durchschnitt ≈28.3% | ≈28.3% | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | 35.4% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | PTCT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.85-Jahres-Durchschnitt ≈0.5 | ≈0.5 | 0.4 | Spitzenklasse | |
| Receivables Turnover (Forderungsumschlag) | 10.25-Jahres-Durchschnitt ≈6.8 | ≈6.8 | 9.7 | Im Einklang | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$1.7M | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
105.2%
Nächster Bericht
Nov 02, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 5, 2026 | $0.92 | $0.43 | 116.4% |
| 31. März 2026 | $-0.03 | $-0.48 | 93.7% | |
| 31. Dezember 2025 | $-1.67 | $0.04 | -4460.3% | |
| 30. September 2025 | $0.20 | $-1.40 | 114.3% | |
| 30. Juni 2025 | $-0.83 | $-1.08 | 23.3% | |
| 31. März 2025 | $10.04 | $-0.22 | 4743.8% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Cost of Revenue | · | · | · | · | · | · | $12M | $13M | $5M | $0 | $0 | · | |
| R&D Expense | $455M | $534M | $667M | $651M | $541M | $478M | $257M | $172M | $117M | $118M | $122M | $80M | |
| SG&A Expense | $347M | $301M | $333M | $326M | $286M | $245M | $203M | $154M | $121M | $97M | $82M | $45M | |
| Operating Expenses | $864M | $1.11B | $1.38B | $1.15B | $913M | $813M | $548M | $380M | $259M | $215M | $204M | $125M | |
| Operating Income | $867M | $-303M | $-440M | $-447M | $-374M | $-432M | $-241M | $-116M | $-64M | $-132M | $-167M | $-99M | |
| Other Non-op | $-18M | $7M | $10M | $-49M | $-58M | $85M | $14M | $129.0K | $-1M | $-1M | $-465.0K | $-213.0K | |
| Pretax Income | $697M | $-363M | $-696M | $-587M | $-518M | $-403M | $-240M | $-128M | $-78M | $-142M | $-170M | $-98M | |
| Income Tax | $14M | $176.0K | $-70M | $-28M | $6M | $35M | $12M | $-29.0K | $1M | $569.0K | $485.0K | $-5M | |
| Net Income | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| EPS (Basic) | $8.58 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-2.75 | $-2.02 | · | · | $-2.97 | |
| EPS (Diluted) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | · | · | · | · | $-2.97 | |
| Shares (Basic) | 79,534,290 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| Shares (Diluted) | 88,311,494 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| EBITDA | $906M | $-227M | $-203M | · | $-310M | $-388M | $-209M | $-90M | $-47M | $-132M | $-167M | $-99M |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $985M | $780M | $594M | $280M | $190M | $209M | $288M | $169M | $112M | $58M | $58M | $50M | |
| Short-term Investments | $961M | $360M | $283M | $131M | $584M | $895M | $399M | $58M | $79M | $173M | $281M | $265M | |
| Receivables | $182M | $159M | $161M | $156M | $110M | $70M | $56M | $68M | $40M | $25M | $11M | $4M | |
| Inventory | $80M | $23M | $31M | $22M | $16M | $19M | $19M | $16M | $11M | $0 | · | · | |
| Prepaid Expense | $67M | $44M | $150M | $106M | $55M | $39M | $18M | $9M | $7M | $5M | $6M | $4M | |
| Current Assets | $2.27B | $1.37B | $1.22B | $694M | $954M | $1.23B | $779M | $321M | $249M | $261M | $356M | $324M | |
| PP&E (Net) | $55M | $61M | $87M | $73M | $53M | $34M | $22M | $13M | $8M | $7M | $9M | $9M | |
| PP&E (Gross) | $102M | $94M | $138M | $110M | $80M | $52M | $33M | $20M | $41M | $38M | $37M | $34M | |
| Accum. Depreciation | $47M | $33M | $51M | $37M | $27M | $18M | $12M | $7M | $33M | $31M | $28M | $25M | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $0 | · | · | · | |
| Intangibles | $389M | $119M | $379M | $706M | $725M | $715M | $710M | $701M | $133M | $0 | · | · | |
| Total Assets | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Accounts Payable | $45M | $17M | $6M | $27M | $23M | $19M | $10M | $6M | $15M | $6M | $6M | $4M | |
| Current Liabilities | $968M | $581M | $603M | $406M | $509M | $277M | $236M | $167M | $82M | $50M | $45M | $32M | |
| Capital Leases | $94M | $75M | $98M | $101M | $74M | $79M | $9M | · | · | · | · | · | |
| Deferred Tax | · | · | $56M | $103M | $137M | $137M | $131M | $122M | $0 | · | · | · | |
| Other Non-current Liabilities | $14M | $21M | $141.0K | $3M | · | $1M | $141.0K | $58.0K | $243.0K | $335.0K | $2M | $2M | |
| Total Liabilities | $3.10B | $2.80B | $2.71B | $2.05B | $1.94B | $1.73B | $1.03B | $768M | $235M | $150M | $139M | $35M | |
| Long-term Debt | · | · | · | · | $431M | · | $314M | $153M | $145M | · | · | · | |
| Total Debt | $287M | $285M | $284M | · | $431M | $309M | $314M | $153M | $145M | $98M | $95M | · | |
| Common Stock | $80.0K | $77.0K | $75.0K | $72.0K | $71.0K | $70.0K | $62.0K | $51.0K | $42.0K | $34.0K | $34.0K | $33.0K | |
| Paid-in Capital | $2.75B | $2.57B | $2.47B | $2.31B | $2.12B | $2.17B | $1.80B | $1.29B | $967M | $856M | $820M | $722M | |
| Retained Earnings | $-2.96B | $-3.65B | $-3.28B | $-2.66B | $-2.10B | $-1.63B | $-1.19B | $-939M | $-814M | $-735M | $-593M | $-423M | |
| AOCI | $11M | $-26M | $-1M | $5M | $-24M | $-61M | $-11M | $1M | $4M | $-1M | $-1M | $-737.0K | |
| Stockholders' Equity | $-205M | $-1.10B | $-819M | $-347M | $1M | $482M | $594M | $351M | $156M | $120M | $226M | $298M | |
| Liabilities + Equity | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Shares Outstanding | 81,474,366 | 77,704,188 | 75,708,889 | 73,104,692 | 70,828,226 | 69,718,096 | 61,935,870 | 50,606,147 | 41,612,395 | 34,169,410 | 33,916,559 | 32,898,392 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $39M | $76M | $237M | $129M | $64M | $43M | $32M | $26M | $18M | $3M | $3M | · | |
| Stock-based Comp | $75M | $75M | $102M | $110M | $104M | $70M | $42M | $33M | $31M | $35M | $34M | $19M | |
| Deferred Tax | $-3.0K | $-56M | $-47M | $-34M | $377.0K | $6M | $9M | $0 | $199.0K | $-199.0K | $0 | $0 | |
| Amort. of Intangibles | $25M | $61M | $223M | $117M | $55M | $37M | $28M | $23M | $15M | $0 | $0 | · | |
| Restructuring | · | · | · | · | · | · | · | · | $0 | · | · | · | |
| Other Non-cash | $-85M | $161M | $177M | · | $105M | $124M | $70M | $41M | $20M | · | · | · | |
| Operating Cash Flow | $711M | $-108M | $-158M | $-357M | $-251M | $-194M | $-99M | $-28M | $-10M | $-104M | $-124M | $-57M | |
| CapEx | $9M | $7M | $28M | $32M | $28M | $18M | $14M | $7M | $3M | $2M | $3M | $5M | |
| Investing Cash Flow | $-862M | $44M | $-177M | $290M | $219M | $-562M | $-387M | $-43M | $13M | $104M | $-21M | $-145M | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | $0 | · | $-49.0K | |
| Stock Issued | · | · | · | · | · | $28M | $324M | $118M | $0 | $0 | $0 | $236M | |
| Net Stock Activity | · | · | · | · | · | $28M | $324M | $118M | · | $0 | · | $236M | |
| Financing Cash Flow | $331M | $256M | $646M | $168M | $21M | $669M | $613M | $132M | $44M | $968.0K | $154M | $237M | |
| Net Change in Cash | $203M | $185M | $314M | $99M | $-19M | $-79M | $126M | $58M | $53M | $299.0K | $8M | $34M | |
| Taxes Paid | $37M | $18M | $14M | $5M | $8M | $26M | $2M | $2M | $1M | $943.0K | $111.0K | $0 | |
| Free Cash Flow | $702M | $-114M | $-187M | · | $-280M | $-212M | $-112M | $-35M | $-13M | $-105M | $-127M | $-62M |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 50.1% | -37.5% | -46.9% | · | -69.5% | -113.4% | -78.6% | -43.7% | -33.1% | -159.7% | -454.6% | -393.8% | |
| Net Margin | 39.4% | -45.0% | -66.8% | · | -97.3% | -115.1% | -82.0% | -48.4% | -40.6% | -171.8% | -463.6% | -371.4% | |
| Pretax Margin | 40.2% | -45.0% | -74.2% | · | -96.2% | -105.8% | -78.2% | -48.4% | -40.0% | -171.1% | -462.3% | -390.0% | |
| EBITDA Margin | 52.3% | -28.1% | -21.6% | · | -57.6% | -102.0% | -68.1% | -33.8% | -24.0% | -159.7% | -454.6% | -393.8% | |
| ROA | 29.7% | -20.2% | -34.8% | · | -25.3% | -22.9% | -18.3% | -17.0% | -23.9% | -44.8% | -48.6% | -38.6% | |
| ROE | -331.5% | 33.8% | 84.1% | · | -985.1% | -88.3% | -40.0% | -34.8% | -57.2% | -82.2% | -65.0% | -43.1% | |
| ROIC | 1044.7% | 37.2% | 74.0% | · | -87.4% | -59.4% | -27.8% | -23.0% | -21.7% | -60.9% | -52.3% | -31.7% |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 2.4 | 2.0 | · | 1.9 | 4.4 | 3.3 | 1.9 | 3.0 | 5.3 | 7.8 | 10.0 | |
| Quick Ratio | 2.2 | 2.2 | 1.7 | · | 1.7 | 4.2 | 3.1 | 1.8 | 2.8 | 5.2 | 7.7 | 9.8 | |
| Debt / Equity | -1.4 | -0.3 | -0.3 | · | 300.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · | |
| LT Debt / Equity | · | -0.3 | -0.3 | · | 196.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.4 | 0.5 | · | 0.3 | 0.2 | 0.2 | 0.4 | 0.6 | 0.3 | 0.1 | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | 0.7 | · | 0.9 | · | · | · | |
| Receivables Turnover | 10.2 | 5.1 | 5.9 | · | 6.0 | 6.1 | 5.0 | 4.9 | 6.0 | 4.6 | 4.7 | 9.3 |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-2.52 | $-14.13 | $-10.81 | · | $0.02 | $6.91 | $9.60 | $6.93 | $3.76 | $3.50 | $6.66 | $9.07 | |
| Revenue / Share | $19.60 | $10.50 | $12.53 | · | $7.64 | · | · | · | · | · | · | $0.80 | |
| Cash Flow / Share | $8.05 | $-1.40 | $-2.12 | · | $-3.57 | · | · | · | · | · | · | $-1.81 | |
| Cash / Share | $12.09 | $10.03 | $7.85 | · | $2.68 | $3.00 | $4.65 | $3.35 | $2.69 | $1.71 | $1.71 | $1.51 | |
| EPS (TTM) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-3.21 | $-3.21 | $-3.21 | $-3.21 | $-2.97 |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 114.5% | -14.0% | 34.2% | 29.8% | 41.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 35.3% | 14.4% | 35.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 35.4% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Net Income TTM | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| Market Cap | $6.19B | $3.51B | $2.09B | · | $2.82B | $4.25B | $2.97B | $1.74B | $694M | $373M | $1.10B | $1.70B | |
| Enterprise Value | $4.53B | $2.65B | $1.49B | · | $2.48B | $3.46B | $2.60B | $1.66B | $648M | $239M | $855M | · | |
| P/E | 9.8 | -9.5 | -3.3 | -4.9 | -5.4 | -9.2 | -11.2 | -10.7 | -5.2 | -3.4 | -10.1 | -17.4 | |
| P/S | 3.6 | 4.3 | 2.2 | · | 5.2 | 11.2 | 9.7 | 6.6 | 3.6 | 4.5 | 29.9 | 67.5 | |
| P/B | -30.1 | -3.2 | -2.5 | · | 1961.8 | 8.8 | 5.0 | 5.0 | 4.4 | 3.1 | 4.9 | 5.7 | |
| P / Cash Flow | 8.7 | -32.6 | -13.2 | · | -11.2 | -21.9 | -30.2 | -62.8 | -69.0 | -3.6 | -8.8 | -29.7 | |
| P / FCF | 8.8 | -30.7 | -11.2 | · | -10.1 | -20.1 | -26.5 | -50.0 | -52.7 | -3.5 | -8.6 | -27.5 | |
| EV / EBITDA | 5.0 | -11.7 | -7.4 | · | -8.0 | -8.9 | -12.5 | -18.6 | -13.9 | -1.8 | -5.1 | · | |
| EV / FCF | 6.5 | -23.2 | -8.0 | · | -8.9 | -16.3 | -23.2 | -47.9 | -49.2 | -2.3 | -6.7 | · | |
| EV / Revenue | 2.6 | 3.3 | 1.6 | · | 4.6 | 9.1 | 8.5 | 6.3 | 3.3 | 2.9 | 23.2 | · | |
| Earnings Yield | 10.2% | -10.5% | -30.4% | -20.4% | -18.6% | -10.9% | -8.9% | -9.3% | -19.2% | -29.4% | -9.9% | -5.7% |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $361M | $273M | $165M | $211M | $179M | $1.18B | $213M | $197M | $187M | $210M | $307M | $197M | $214M | $220M | $167M | $217M | |
| R&D Expense | $99M | $101M | $133M | $100M | $113M | $109M | $125M | $161M | $132M | $116M | $121M | $164M | $186M | $195M | $189M | $165M | |
| SG&A Expense | $81M | $86M | $97M | $84M | $85M | $81M | $85M | $73M | $70M | $73M | $76M | $81M | $88M | $87M | $93M | $80M | |
| Operating Expenses | $212M | $228M | $236M | $208M | $214M | $206M | $376M | $251M | $227M | $256M | $301M | $315M | $423M | $338M | $368M | $285M | |
| Operating Income | $149M | $45M | $-71M | $3M | $-35M | $970M | $-162M | $-55M | $-40M | $-45M | $6M | $-118M | $-210M | $-118M | $-200M | $-68M | |
| Other Non-op | $-3M | $2M | $-13M | $7M | $-6M | $-6M | $9M | $-2M | $-2M | $2M | $19M | $-20M | $1M | $10M | $35M | $-38M | |
| Pretax Income | $98M | $-2M | $-139M | $-23M | $-71M | $930M | $-95M | $-98M | $-86M | $-85M | $-157M | $-167M | $-237M | $-135M | $-190M | $-127M | |
| Income Tax | $14M | $347.0K | $-4M | $-39M | $-6M | $63M | $-29M | $9M | $13M | $7M | $-1M | $-34M | $-39M | $4M | $-19M | $-18M | |
| Net Income | $83M | $-3M | $-135M | $16M | $-65M | $867M | $-66M | $-107M | $-99M | $-92M | $-156M | $-133M | $-199M | $-139M | $-171M | $-109M | |
| EPS (Basic) | $1.01 | $-0.03 | $-1.88 | $0.20 | $-0.83 | $11.09 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| EPS (Diluted) | $0.92 | $-0.03 | $-1.63 | $0.20 | $-0.83 | $10.04 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| Shares (Basic) | 83,006,808 | 82,521,023 | · | 78,471,119 | 78,151,240 | 78,115,836 | · | 76,925,523 | 76,725,070 | 76,496,127 | · | 75,377,997 | 74,730,433 | 73,729,284 | · | 71,654,671 | |
| Shares (Diluted) | 92,020,009 | 82,521,023 | · | 87,115,369 | 78,151,240 | 86,385,922 | · | 76,925,523 | 76,725,070 | 76,496,127 | · | 75,377,997 | 74,730,433 | 73,729,284 | · | 71,654,671 | |
| EBITDA | $149M | $60M | · | $3M | $-35M | $977M | · | $-55M | $-40M | $10M | · | $-118M | $-210M | $-75M | · | $-68M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.05B | $834M | $985M | $673M | $1.02B | $1.48B | $780M | $526M | $655M | $548M | · | $165M | $208M | $167M | · | $104M | |
| Short-term Investments | $1.18B | $1.06B | $961M | $1.02B | $972M | $547M | $360M | $487M | $439M | $336M | · | $130M | $130M | $119M | · | $184M | |
| Receivables | $239M | $220M | $182M | $203M | $196M | $210M | $159M | $200M | $187M | $198M | · | $166M | $178M | $202M | · | $124M | |
| Inventory | $91M | $76M | $80M | $53M | $34M | $22M | $23M | $36M | $32M | $30M | · | $36M | $32M | $27M | · | $15M | |
| Prepaid Expense | $58M | $66M | $67M | $64M | $54M | $57M | $44M | $33M | $46M | $56M | · | $44M | $42M | $99M | · | $90M | |
| Current Assets | $2.62B | $2.25B | $2.27B | $2.01B | $2.27B | $2.32B | $1.37B | $1.28B | $1.36B | $1.17B | · | $540M | $590M | $613M | · | $517M | |
| PP&E (Net) | $51M | $53M | $55M | $57M | $57M | $59M | $61M | $63M | $66M | $93M | · | $85M | $82M | $79M | · | $67M | |
| PP&E (Gross) | · | · | $102M | · | · | · | $94M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $33M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | · | $82M | $82M | $82M | · | $82M | |
| Intangibles | $403M | $381M | $389M | $396M | $144M | $118M | $119M | $330M | $330M | $330M | · | $423M | $452M | $686M | · | $750M | |
| Total Assets | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Accounts Payable | $40M | $25M | $45M | $37M | $27M | $15M | $17M | $13M | $24M | $27M | · | $19M | $26M | $26M | · | $21M | |
| Current Liabilities | $771M | $924M | $968M | $866M | $628M | $595M | $581M | $611M | $610M | $575M | · | $492M | $476M | $442M | · | $420M | |
| Capital Leases | $88M | $90M | $94M | $95M | $71M | $74M | $75M | $83M | $79M | $105M | · | $100M | $100M | $100M | · | $102M | |
| Deferred Tax | · | · | · | · | · | · | · | $56M | $56M | $56M | · | $52M | $52M | $103M | · | $137M | |
| Other Non-current Liabilities | $15M | $14M | $14M | $3M | $8M | $22M | $21M | $77.0K | $141.0K | $141.0K | · | $141.0K | $141.0K | $141.0K | · | $5M | |
| Total Liabilities | $3.42B | $3.05B | $3.10B | $2.80B | $2.84B | $2.84B | $2.80B | $2.90B | $2.90B | $2.68B | · | $1.93B | $1.92B | $2.07B | · | $1.80B | |
| Long-term Debt | $591M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $591M | $287M | · | $286M | $286M | $286M | · | $285M | $285M | $285M | · | $573M | $573M | $572M | · | $283M | |
| Common Stock | $82.0K | $81.0K | $80.0K | $79.0K | $78.0K | $78.0K | $77.0K | $76.0K | $76.0K | $76.0K | · | $75.0K | $75.0K | $73.0K | · | $71.0K | |
| Paid-in Capital | $2.71B | $2.78B | $2.75B | $2.67B | $2.63B | $2.61B | $2.57B | $2.53B | $2.51B | $2.49B | · | $2.45B | $2.42B | $2.34B | · | $2.22B | |
| Retained Earnings | $-2.88B | $-2.97B | $-2.96B | $-2.83B | $-2.85B | $-2.78B | $-3.65B | $-3.58B | $-3.47B | $-3.38B | · | $-3.13B | $-2.99B | $-2.80B | · | $-2.49B | |
| AOCI | $6M | $8M | $11M | $6M | $7M | $-14M | $-26M | $-4M | $-16M | $-6M | · | $10M | $-1M | $-2M | · | $36M | |
| Stockholders' Equity | $-165M | $-180M | $-205M | $-156M | $-207M | $-186M | $-1.10B | $-1.05B | $-980M | $-894M | $-819M | $-671M | $-579M | $-458M | $-347M | $-227M | |
| Liabilities + Equity | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Shares Outstanding | 83,327,286 | 82,882,024 | 81,474,366 | 79,931,766 | 79,378,145 | 79,225,276 | 77,704,188 | 76,952,124 | 76,900,123 | 76,653,960 | · | 75,459,022 | 75,318,233 | 74,012,034 | · | 71,854,892 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $16M | $15M | $13M | $11M | $8M | $7M | $7M | $6M | $7M | $55M | $81M | $62M | $51M | $43M | $39M | $34M | |
| Stock-based Comp | $23M | $23M | $19M | $19M | $19M | $18M | $17M | $20M | $19M | $18M | $17M | $27M | $29M | $29M | $27M | $29M | |
| Deferred Tax | · | $-10.0K | $1.0K | · | · | $2.0K | $-56M | $-3.0K | $2.0K | $-1.0K | $4M | $-2.0K | $-51M | $-4.0K | · | · | |
| Amort. of Intangibles | $12M | $12M | $9M | $8M | $4M | $4M | $3M | $3M | $3M | $52M | $77M | $59M | $47M | $39M | $36M | $31M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $23M | $8M | · | · | · | |
| Other Non-cash | · | $-95M | · | · | · | $-22M | · | · | · | $89M | · | · | · | $38M | · | · | |
| Operating Cash Flow | $129M | $-59M | $-34M | $-66M | $-58M | $870M | $-30M | $-77M | $-71M | $71M | $-100M | $-15M | $-14M | $-29M | $-166M | $-38M | |
| CapEx | $2M | $1M | $2M | $3M | $1M | $2M | $4M | $522.0K | $-7M | $10M | $6M | $6M | $6M | $10M | $9M | $5M | |
| Investing Cash Flow | $-123M | $-94M | $34M | $-290M | $-422M | $-184M | $268M | $-43M | $-66M | $-115M | $-94M | $-30M | $-24M | $-29M | $32M | $136M | |
| Financing Cash Flow | $212M | $6M | $303M | $15M | $4M | $9M | $26M | $-18M | $246M | $540.0K | $620M | $3M | $18M | $4M | $303M | $-140M | |
| Net Change in Cash | $216M | $-148M | $312M | $-347M | $-463M | $701M | $256M | $-129M | $104M | $-46M | $429M | $-43M | $-9M | $-62M | $175M | $-54M | |
| Taxes Paid | · | · | $-3M | $936.0K | $36M | $3M | $5M | $7M | $4M | $2M | $524.0K | $4M | $7M | $2M | $893.0K | $1M | |
| Free Cash Flow | · | $-60M | · | · | · | $868M | · | · | · | $61M | · | · | · | $-40M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 41.3% | 16.5% | · | 1.4% | -19.5% | 82.5% | · | -27.7% | -21.5% | -21.6% | · | -60.1% | -98.0% | -53.4% | · | -31.4% | |
| Net Margin | 23.2% | -1.0% | · | 7.5% | -36.2% | 73.7% | · | -54.2% | -53.1% | -43.6% | · | -67.6% | -93.0% | -63.0% | · | -50.3% | |
| Pretax Margin | 27.1% | -0.90% | · | -10.9% | -39.7% | 79.1% | · | -49.8% | -45.9% | -40.3% | · | -84.8% | -111.1% | -61.3% | · | -58.6% | |
| EBITDA Margin | 41.3% | 22.1% | · | 1.4% | -19.5% | 83.1% | · | -27.7% | -21.5% | 4.7% | · | -60.1% | -98.0% | -33.9% | · | -31.4% | |
| ROA | 2.8% | -0.10% | · | 0.71% | -2.9% | 39.0% | · | -6.9% | -6.1% | -5.4% | · | -9.4% | -12.7% | -8.2% | · | -6.1% | |
| ROE | -44.9% | 1.5% | · | -2.6% | 10.9% | -160.5% | · | 12.4% | 12.7% | 13.6% | · | 29.6% | 52.2% | 50.7% | · | 179.2% | |
| ROIC | 30.0% | 48.2% | · | -1.6% | -40.2% | 904.6% | · | 7.7% | 6.7% | 8.1% | · | 96.6% | 2648.9% | -105.7% | · | -104.9% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 2.4 | · | 2.3 | 3.6 | 3.9 | · | 2.1 | 2.2 | 2.0 | · | 1.1 | 1.2 | 1.4 | · | 1.2 | |
| Quick Ratio | 3.2 | 2.3 | · | 2.2 | 3.5 | 3.8 | · | 2.0 | 2.1 | 1.9 | · | 0.9 | 1.1 | 1.1 | · | 1.0 | |
| Debt / Equity | -3.6 | -1.6 | · | -1.8 | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 | |
| LT Debt / Equity | -3.2 | · | · | · | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.5 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.7 | 1.3 | · | 1.0 | 0.9 | 5.8 | · | 1.1 | 1.0 | 1.1 | · | 1.4 | 1.4 | 1.3 | · | 2.0 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-1.98 | $-2.18 | · | $-1.95 | $-2.60 | $-2.34 | · | $-13.70 | $-12.75 | $-11.66 | · | $-8.89 | $-7.69 | $-6.18 | · | $-3.16 | |
| Revenue / Share | $3.92 | $3.30 | · | $2.42 | $2.29 | $13.61 | · | $2.56 | $2.43 | $2.75 | · | $2.61 | $2.86 | $2.99 | · | $3.03 | |
| Cash Flow / Share | · | $-0.72 | · | · | · | $10.07 | · | · | · | $0.93 | · | · | · | $-0.40 | · | · | |
| Cash / Share | $12.60 | $10.06 | · | $8.41 | $12.82 | $18.68 | · | $6.84 | $8.51 | $7.15 | · | $2.19 | $2.77 | $2.26 | · | $1.45 | |
| EPS (TTM) | $-0.54 | $-2.29 | · | $8.56 | $6.97 | $6.51 | · | $-5.95 | $-6.32 | $-7.69 | · | $-8.65 | $-8.42 | $-7.89 | · | $-7.47 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.01B | $827M | · | $1.78B | $1.76B | $1.77B | · | $901M | $900M | $928M | · | $798M | $819M | $770M | · | $697M | |
| Net Income TTM | $-38M | $-187M | · | $752M | $629M | $595M | · | $-453M | $-480M | $-579M | · | $-642M | $-618M | $-571M | · | $-531M | |
| Market Cap | $6.80B | $5.65B | · | $4.91B | $3.88B | $4.04B | · | $2.85B | $2.35B | $2.23B | · | $1.69B | $3.06B | $3.59B | · | $3.61B | |
| Enterprise Value | $5.16B | $4.04B | · | $3.50B | $2.17B | $2.30B | · | $2.13B | $1.54B | $1.63B | · | $1.97B | $3.30B | $3.87B | · | $3.60B | |
| P/E | -151.1 | -29.8 | · | 7.2 | 7.0 | 7.8 | · | -6.2 | -4.8 | -3.8 | · | -2.6 | -4.8 | -6.1 | · | -6.7 | |
| P/S | 6.7 | 6.8 | · | 2.8 | 2.2 | 2.3 | · | 3.2 | 2.6 | 2.4 | · | 2.1 | 3.7 | 4.7 | · | 5.2 | |
| P/B | -41.1 | -31.3 | · | -31.5 | -18.8 | -21.7 | · | -2.7 | -2.4 | -2.5 | · | -2.5 | -5.3 | -7.8 | · | -15.9 | |
| P / Cash Flow | · | -95.6 | · | · | · | 4.6 | · | · | · | 31.5 | · | · | · | -121.6 | · | · | |
| EV / Revenue | 5.1 | 4.9 | · | 2.0 | 1.2 | 1.3 | · | 2.4 | 1.7 | 1.8 | · | 2.5 | 4.0 | 5.0 | · | 5.2 | |
| Earnings Yield | -0.66% | -3.4% | · | 14.0% | 14.3% | 12.8% | · | -16.0% | -20.7% | -26.4% | · | -38.6% | -20.7% | -16.3% | · | -14.9% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $1.73B | $807M | $938M | $699M | $539M |
| Betriebsgewinnmarge % | 50.1% | -37.5% | -46.9% | · | -69.5% |
| Nettoergebnis | $683M | $-363M | $-627M | $-559M | $-524M |
| Verwässerte EPS | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | -1.4 | -0.3 | -0.3 | · | 300.0 |
| Liquiditätsgrad | 2.3 | 2.4 | 2.0 | · | 1.9 |
| Quick Ratio | 2.2 | 2.2 | 1.7 | · | 1.7 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $702M | $-114M | $-187M | · | $-280M |
Institutionelle Eigentümer (13F) 403 Einreicher · $8.6B gesamt · Stand 30. September 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
403
Gehaltener Wert
$8.6B
Neue Positionen
76
Geschlossene Positionen
43
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 76 (+7 vs. Vorquartal) | 43 (-7 vs. Vorquartal) | 140 (+3 vs. Vorquartal) | 114 (+10 vs. Vorquartal) | -1.4M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| BlackRock, Inc. | $1.139.088.671 | 13.964.554 | 13,21% | Aktien |
| VANGUARD GROUP INC | $668.691.300 | 8.803.203 | 7,75% | Aktien |
| RTW INVESTMENTS, LP | $631.875.072 | 7.746.415 | 7,33% | Aktien |
| JANUS HENDERSON GROUP PLC | $489.997.100 | 7.193.433 | 5,68% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $401.986.014 | 4.928.111 | 4,66% | Aktien |
| STATE STREET CORP | $375.136.515 | 4.598.952 | 4,35% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $336.743.228 | 4.128.273 | 3,90% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $305.000.589 | 3.739.127 | 3,54% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $180.089.116 | 2.207.376 | 2,09% | Aktien |
| TORONTO DOMINION BANK | $176.668.031 | 2.165.846 | 2,05% | Aktien |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $159.563.645 | 1.956.156 | 1,85% | Aktien |
| Hood River Capital Management LLC | $141.818.662 | 1.738.613 | 1,64% | Aktien |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $140.519.660 | 1.722.688 | 1,63% | Aktien |
| D. E. Shaw & Co., Inc. | $126.345.323 | 1.548.919 | 1,47% | Aktien |
| TANG CAPITAL MANAGEMENT LLC | $122.355.000 | 1.500.000 | 1,42% | Aktien |
| BANK OF AMERICA CORP /DE/ | $118.462.234 | 1.452.277 | 1,37% | Aktien |
| Driehaus Capital Management LLC | $117.469.528 | 1.440.107 | 1,36% | Aktien |
| FMR LLC | $114.056.206 | 1.398.261 | 1,32% | Aktien |
| Jefferies Financial Group Inc. | $110.693.916 | 1.357.042 | 1,28% | Aktien |
| FULLER & THALER ASSET MANAGEMENT, INC. | $94.361.749 | 1.156.819 | 1,09% | Aktien |
| Pictet Asset Management Holding SA | $93.629.635 | 1.147.844 | 1,09% | Aktien |
| MORGAN STANLEY | $90.026.886 | 1.103.675 | 1,04% | Aktien |
| ARMISTICE CAPITAL, LLC | $87.393.690 | 1.071.395 | 1,01% | Aktien |
| Blue Sparrow, LLC /DE | $85.705.599 | 1.050.700 | 0,99% | Aktien |
| FRANKLIN RESOURCES INC | $83.799.082 | 1.027.327 | 0,97% | Aktien |
| Invesco Ltd. | $76.804.761 | 941.581 | 0,89% | Aktien |
| Palo Alto Investors LP | $74.950.268 | 918.846 | 0,87% | Aktien |
| NORTHERN TRUST CORP | $71.783.966 | 880.029 | 0,83% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $64.449.436 | 790.112 | 0,75% | Aktien |
| CITADEL ADVISORS LLC | $60.999.840 | 747.822 | 0,71% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $59.015.895 | 723.500 | 0,68% | Aktien |
| Boston Partners | $58.606.553 | 718.574 | 0,68% | Aktien |
| JUPITER ASSET MANAGEMENT LTD | $57.706.697 | 707.450 | 0,67% | Aktien |
| MARSHALL WACE, LLP | $57.489.476 | 704.787 | 0,67% | Aktien |
| JPMORGAN CHASE & CO | $56.073.502 | 684.042 | 0,65% | Aktien |
| ARMISTICE CAPITAL, LLC | $53.836.200 | 660.000 | 0,62% | Kaufoption |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $53.377.940 | 654.382 | 0,62% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $52.017.434 | 637.704 | 0,60% | Aktien |
| GOLDMAN SACHS GROUP INC | $50.430.408 | 618.247 | 0,58% | Aktien |
| LOOMIS SAYLES & CO L P | $48.156.807 | 590.374 | 0,56% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $47.953.943 | 587.887 | 0,56% | Aktien |
| Nuveen, LLC | $47.622.931 | 583.829 | 0,55% | Aktien |
| Bank of New York Mellon Corp | $45.145.865 | 553.462 | 0,52% | Aktien |
| PRINCIPAL FINANCIAL GROUP INC | $44.181.166 | 541.635 | 0,51% | Aktien |
| VOYA INVESTMENT MANAGEMENT LLC | $43.992.251 | 539.319 | 0,51% | Aktien |
| Ensign Peak Advisors, Inc | $41.442.128 | 508.056 | 0,48% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $40.866.277 | 500.995 | 0,47% | Aktien |
| FEDERATED HERMES, INC. | $39.432.896 | 483.424 | 0,46% | Aktien |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $36.050.432 | 441.957 | 0,42% | Aktien |
| Parkman Healthcare Partners LLC | $35.539.315 | 435.691 | 0,41% | Aktien |
Aktivisten & 5%+-Eigentümer 3 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Brookside Capital Partners Fund, L.P., Brookside Capital Trading Fund, L.P. ×5 Einreichungen | 30. Januar 2015 | · | Erste Einreichung | · | SEC |
| HBM Healthcare Investments (Cayman) Ltd. (“HBM”) ×2 Einreichungen | 12. November 2014 | · | Erste Einreichung | · | SEC |
| HBM Healthcare Investments (Cayman) Ltd. | 5. Juli 2013 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 37 Insider · 15 Führungskräfte · 20 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Matthew B. Klein | CHIEF EXECUTIVE OFFICER | 4. August 2026 S | 383.868 | 0 | 13 | $-4.219.888 |
| Stuart Walter Peltz | CHIEF EXECUTIVE OFFICER | 31. Januar 2023 S | 54.903 | 0 | 0 | $0 |
| Pierre Gravier | CHIEF FINANCIAL OFFICER | 14. Juli 2026 S | 83.986 | 0 | 3 | $-652.864 |
| Emily Luisa Hill | CHIEF FINANCIAL OFFICER | 27. März 2023 S | 38.925 | 0 | 0 | $0 |
| Shane William Charles Kovacs | Chief Financial Officer | 9. Mai 2017 M | 37.850 | 0 | 0 | $0 |
| Claudia De Oliveira Ribeiro Hirawat | President | 15. Januar 2015 M | 39.247 | 0 | 0 | $0 |
| Marcio Souza | Chief Operating Officer | 10. Februar 2020 M | 6.744 | 0 | 0 | $0 |
| Mark Elliott Boulding | EXEC. VP AND CLO | 17. August 2026 M | 105.272 | 0 | 63 | $-5.955.553 |
| Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | 9. Juli 2026 M | 60.299 | 0 | 62 | $-25.989.291 |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 17. Juni 2026 M | 70.199 | 0 | 5 | $-1.941.426 |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 10. Juni 2026 S | 73.411 | 0 | 28 | $-7.477.160 |
| Lee Scott Golden | EVP & CHIEF MEDICAL OFFICER | 2. April 2026 S | 79.115 | 0 | 6 | $-1.081.515 |
| Mark Rothera | Chief Commercial Officer | 24. Mai 2017 M | 33.739 | 0 | 0 | $0 |
| Tuyen Ong | Chief Medical Officer | 3. Januar 2017 A | 6.000 | 0 | 0 | $0 |
| Robert J. Spiegel | Chief Medical Officer | 4. Januar 2016 A | 3.239 | 0 | 0 | $0 |
| Glenn Steele JR MD PHD | Direktor | 30. September 2026 M | 22.500 | 0 | 2 | $-1.698.120 |
| Michael Schmertzler | Direktor | 17. September 2026 S | 1.296.594 | 0 | 16 | $-6.313.453 |
| Hege Elisabeth Sollie-Zetlmayer | Direktor | 28. Juli 2026 A | 52.526 | 0 | 0 | $0 |
| Mary L. Smith | Direktor | 9. Juli 2026 M | 21.813 | 0 | 2 | $-1.425.060 |
| Jessica Caroline Chutter | Direktor | 24. März 2026 A | 7.333 | 0 | 0 | $0 |
| Stephanie Okey | Direktor | 10. März 2026 M | 8.000 | 0 | 3 | $-1.463.076 |
| Emma Reeve | Direktor | 5. Januar 2026 M | 10.666 | 0 | 15 | $-4.229.530 |
| Alethia Young | Direktor | 2. Januar 2026 A | 21.067 | 0 | 0 | $0 |
| Allan Steven Jacobson | Direktor | 2. Januar 2026 A | 21.451 | 0 | 11 | $-2.912.018 |
| Jerome B Zeldis | Direktor | 2. Januar 2026 A | 22.500 | 0 | 0 | $0 |
| William F. Bell Jr. | Direktor | 15. Februar 2024 A | 10.333 | 0 | 0 | $0 |
| Dawn Svoronos | Direktor | 9. Juni 2022 S | 29.017 | 0 | 0 | $0 |
| Cameron Geoffrey Mcdonough | Direktor | 3. Januar 2017 A | · | 0 | 0 | $0 |
| Adam Koppel | Direktor | 3. Januar 2017 A | 2.333.333 | 0 | 0 | $0 |
| Ronald C Renaud JR | Direktor | 3. Januar 2017 A | · | 0 | 0 | $0 |
| Richard Aldrich | Direktor | 8. Juni 2015 M | 0 | 0 | 0 | $0 |
| Michael L Kranda | Direktor | 16. März 2015 S | 2.242 | 0 | 0 | $0 |
| Axel Bolte | Direktor | 25. Juni 2013 P | 20.000 | 0 | 0 | $0 |
| HBM Healthcare Investments (Cayman) Ltd. | 10%-Eigentümer | 17. Dezember 2013 S | 2.441.504 | 0 | 0 | $0 |
| David P Southwell | · | 2. Januar 2026 A | 20.850 | 0 | 0 | $0 |
| Complete Pharma Holdings II, LLC | · | 28. April 2017 J | 0 | 0 | 0 | $0 |
| CREDIT SUISSE/ | · | 25. Juni 2013 C | 2.256.882 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 68 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IBRN · iShares Trust | 3,74% | 4.145 SH | 11. September 2026 | Täglich |
| PSCH · Invesco Exchange-Traded Fund Trust … | 2,93% | 79.357 SH | 2. Oktober 2026 | Täglich |
| PBE · Invesco Exchange-Traded Fund Trust | 2,47% | 159.717 SH | 2. Oktober 2026 | Täglich |
| MEDI · Harbor ETF Trust | 1,31% | 7.913 NS | 31. Juli 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,25% | 18.062 NS | 31. Juli 2026 | N-PORT |
| RZG · Invesco Exchange-Traded Fund Trust | 1,23% | 22.852 SH | 2. Oktober 2026 | Täglich |
| JSML · Janus Detroit Street Trust | 1,03% | 54.825 NS | 31. Juli 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 0,94% | 145.033 NS | 31. Juli 2026 | N-PORT |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,74% | 98.733 SH | 19. August 2026 | Täglich |
| VAMO · Cambria ETF Trust | 0,72% | 11.494 NS | 31. Juli 2026 | N-PORT |
| VMAX · Lattice Strategies Trust | 0,71% | 5.120 NS | 31. Juli 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,63% | 46.006 NS | 31. Juli 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0,49% | 658 NS | 31. Juli 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,42% | 3.031 NS | 31. Juli 2026 | N-PORT |
| IBB · iShares Trust | 0,40% | 613.266 SH | 11. September 2026 | Täglich |
| BRNY · EA Series Trust | 0,39% | 33.006 NS | 31. Juli 2026 | N-PORT |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,37% | 290.018 SH | 19. August 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,36% | 5.891 SH | 2. Oktober 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,34% | 75.795 SH | 19. August 2026 | Täglich |
| ESSC · Strategy Shares | 0,34% | 1.785 NS | 31. Juli 2026 | N-PORT |
| IWO · iShares Trust | 0,31% | 664.357 SH | 11. September 2026 | Täglich |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,27% | 22.505 NS | 31. Juli 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0,25% | 25.676 NS | 31. Juli 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,24% | 3.125 NS | 31. Juli 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,20% | 477.030 SH | 19. August 2026 | Täglich |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,19% | 19.797 NS | 31. Juli 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,19% | 3.667 NS | 31. Juli 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,19% | 1.099.640 SH | 19. August 2026 | Täglich |
| IWM · iShares Trust | 0,18% | 2.118.779 SH | 11. September 2026 | Täglich |
| RSSL · Global X Funds | 0,18% | 39.691 NS | 31. Juli 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0,18% | 629 NS | 31. Juli 2026 | N-PORT |
| ISCG · iShares Trust | 0,16% | 23.005 SH | 11. September 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,16% | 65.468 SH | 2. Oktober 2026 | Täglich |
| LRGF · iShares Trust | 0,16% | 84.774 SH | 11. September 2026 | Täglich |
| VFMO · VANGUARD WELLINGTON FUND | 0,14% | 35.428 SH | 19. August 2026 | Täglich |
| FSMD · FIDELITY COVINGTON TRUST | 0,14% | 51.459 NS | 31. Juli 2026 | N-PORT |
| FHEQ · Fidelity Greenwood Street Trust | 0,14% | 18.636 NS | 31. Juli 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,13% | 5.320 SH | 2. Oktober 2026 | Täglich |
| FBUF · Fidelity Greenwood Street Trust | 0,12% | 413 NS | 31. Juli 2026 | N-PORT |
| FYEE · Fidelity Greenwood Street Trust | 0,11% | 3.600 NS | 31. Juli 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,10% | 224.327 NS | 31. Juli 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,08% | 952.071 SH | 19. August 2026 | Täglich |
| VB · VANGUARD INDEX FUNDS | 0,08% | 1.902.509 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,08% | 211.842 SH | 19. August 2026 | Täglich |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,08% | 6.756 NS | 31. Juli 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,07% | 33.487 NS | 31. Juli 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,06% | 12.627 NS | 31. Juli 2026 | N-PORT |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0,06% | 18.932 SH | 2. Oktober 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,06% | 10.557 SH | 19. August 2026 | Täglich |
| ESML · iShares Trust | 0,06% | 22.893 SH | 11. September 2026 | Täglich |
| WSML · iShares Trust | 0,04% | 4.360 SH | 11. September 2026 | Täglich |
| TILT · FlexShares Trust | 0,01% | 4.108 NS | 31. Juli 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,01% | 2.636.335 SH | 19. August 2026 | Täglich |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 66.405 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 6.819 SH | 19. August 2026 | Täglich |
| ESGV · VANGUARD WORLD FUND | 0,01% | 18.275 SH | 19. August 2026 | Täglich |
| ITOT · iShares Trust | 0,01% | 109.219 SH | 11. September 2026 | Täglich |
| IWV · iShares Trust | 0,01% | 22.686 SH | 10. September 2026 | Täglich |
| DFAC · Dimensional ETF Trust | 0,01% | 43.296 NS | 31. Juli 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 1.090 NS | 31. Juli 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 284 NS | 31. Juli 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 249 NS | 31. Juli 2026 | N-PORT |
| IJR · iShares Trust | · | 5.061.986 SH | 10. September 2026 | Täglich |
| IJT · iShares Trust | · | 784.746 SH | 9. September 2026 | Täglich |
| IWN · iShares Trust | · | 114.658 SH | 11. September 2026 | Täglich |
| XJR · iShares Trust | · | 11.464 SH | 31. August 2026 | Täglich |
| ISCB · iShares Trust | · | 3.281 SH | 11. September 2026 | Täglich |
| SMLF · iShares Trust | · | 64.380 SH | 11. September 2026 | Täglich |
PTCT Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 21 Analysten
KAUF
Median-Ziel
$101.00
+59,2%
6 28,6%
Starker Kauf
11 52,4%
Kauf
3 14,3%
Halten
1 4,8%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
14 Analysten · 2026-10-01Mittelwert-Ziel $101.79 +60,4%
← Unter allen Zielen
Aktueller Preis $63.46
Tief$70.00
Mittelwert$101.79
Hoch$137.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| PTCT | $6.19B | 9.8 | 114.5% | 39.4% | -331.5% | · |
| SRRK | $4.78B | -13.4 | · | · | -157.9% | · |
| ORKA | $1.48B | -3.3 | · | · | -25.9% | · |
| COGT | $5.72B | -16.4 | · | · | -83.1% | · |
| MIRM | $4.10B | -168.1 | 54.7% | -4.5% | -8.2% | · |
| TVTX | $3.47B | -131.8 | 110.5% | -5.2% | -34.6% | · |
| ERAS | $1.06B | -8.5 | · | · | -35.7% | · |
| DNTH | $1.78B | -9.8 | -67.3% | -7973.3% | -40.8% | · |
| RLAY | $1.47B | -5.3 | 53.4% | -1800.6% | -44.9% | · |
Handelssignale Aktuelle Kauf-/Verkaufssignale mit Einstiegspreis und Risiko-Ertrags-Verhältnis
Derzeit kein offenes Signal – keine Karte ist ausgefüllt, und das ist ehrlich.
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Jul 30, 2026